2nd International Bladder Cancer Update

Avon, CO US
January 27, 2018

In conjunction with the Medical College of Wisconsin (MCW), Carden Jennings Publishing Co.,Ltd. (CJP) proposes to develop a live conference on the topic of bladdercancer. This conference will encompass expert lectures, interactive discussions, a panel roundtable, debates, and case reports. It will be physician-led, multi-supported, and designed for urologists, medical oncologists, and other healthcare professionals involved in the treatment of bladder cancer. This conference will be the 1st annual International Bladder Cancer Update (IBCU1), and is being held at The Westin Riverfront at Beaver Creek, CO from January 24, 2017. This activity will be a Sunshine-exempt, CME-accredited educational program. As such, it will meet the following requirements: (1) the provider and program is accredited, (2) no direct payments are allowed between CME supporters and physician faculty, and (3) CME supporters have no role in directing, suggesting, or implementing how the proceeds of the grant are used by the CME provider.

Program Goal
The goal of this educational program is to equip urologists, medical oncologists, and other healthcare professionals involved in the treatment of bladder cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of bladder cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating bladder cancer patients, and to give them a chance to discuss the issues with peers and experts.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians. 

The Medical College of Wisconsin designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 

Target Audience

This activity has been developed and is intended for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of bladder cancer.

Learning Objectives

The following are the learning objectives in CME format for this program. Upon completion of
this program, participants will be able to effectively address:

  • new clinical practice guidelines
  • Current best practices in prevention and screening of bladder cancer
  • Updates on the use of biomarkers
  • Promising therapies
  • Issues and economic concerns in the tratment of low and high risk patients
  • The sequencing of available therapies in 2016
Additional information

Contact

Name: 
David Utz
Phone Number: 
+1 (434) 817-2000
Email: 
[email protected]
Course summary
Available credit: 
  • 5.75 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 5.75 Hours of Participation
    Hours of Participation credit.
Course opens: 
01/01/2018
Course expires: 
04/15/2018
Event starts: 
01/27/2018 - 10:00am CST
Event ends: 
01/27/2018 - 6:30pm CST
Cost:
$0.00
Add to calendar: 

Saturday, January 27, 2018

7:00 AM – 8:00 AM              Educational Breakfast Symposium – Supported by UroGen Maya Restaurant

8:00 AM – 4:00 PM              2nd International Bladder Cancer Update

                                                                   Michael S. Cookson, MD, MMHC (Co-Chair) 

                                                                   Daniel P. Petrylak, MD (Co-Chair)

8:00 AM – 1:00 PM               Non-muscle Invasive Bladder Session

8:00 AM – 8:10 AM               Welcome and Introduction, Michael S. Cookson, MD, MMHC

8:10 AM – 8:30 AM               Clinical Trials for NMIBC, Ashish M. Kamat, MD, MBBS, FACS

8:30 AM – 8:50 AM               Urinary Markers in Bladder Cancer, Peter Black, MD

8:50 AM – 9:10 AM               Enhanced Techniques of NMIBC Detection, Michael S. Cookson, MD, MMHC

9:10 AM – 9:30 AM             BCG Unresponsive Disease – A Roadmap for Drug Development and Integration of Novel Therapies

                                                                Seth P. Lerner, MD

9:30 AM – 9:50 AM               Coffee Break and Visit Exhibits - Riverside Foyer

9:50 AM – 10:20 AM             Panel Discussion - Moderator: Michael Cookson, MD, MMHC 

                                                                 Panelists: Lerner, Black, Chang, Kamat

10:20 AM – 2:00 PM             Invasive and Advanced Bladder Session: Part I

10:20 AM – 10:40 AM           MIBC Guidelines Review, Sam S. Chang, MD

10:40 AM – 11:00 AM           Perioperative Pathways: What We Know Works, Peter Black, MD

11:00 AM – 12:00 PM            Surgical Approach: Robotic v. Open, Sam S. Chang, MD, MBA

12:00 PM– 12:45 PM            Educational Lunch Symposium – The Expanding Role of

                                                    Immunotherapy in Bladder Cancer Treatment 

                                                         Supported by Pfizer, Maya Restaurant

12:45 PM – 1:00 PM             Break and Visit Exhibits - Riverside Foyer

1:00 PM – 2:00 PM               Invasive and Advanced Bladder Session: Part II

1:00 PM – 1:20 PM            Basic Science in Bladder Cancer Diagnosis and Treatment, Daniel Theodorescu, MD, PhD

1:20 PM – 1:40 PM               Thromboembolic Complications in Bladder Cancer, Jehonathan Pinthus, MD

1:40 PM – 2:00 PM               Systematic ImmunoOncologics (IOs): Checkpoint Inhibition for High Risk Disease 

                                                                 Daniel P. Petrylak, MD

2:00 PM – 2:30 PM               Break and Exhibits – Riverside Foyer

2:30 PM – 4:00PM                Invasive and Advanced Bladder Session: Part III

2:20 PM – 2:40 PM              Neoadjuvant/Adjuvant Chemotherapy: Are We Ready to Accept Neoadjuvant as the Gold Standard? 

                                                               Seth P. Lerner, MD

2:40 PM – 3:00 PM               Should Variant Histology Change Management of Bladder Cancer? 

                                               Ashish M. Kamat, MD, MBBS, FACS

3:00 PM – 3:20 PM               Update on Checkpoint Inhibitors, Daniel P. Petrylak, MD

3:20 PM – 3:40 PM               Basic Concepts in Bladder Cancer Immunotherapy, Leonard G. Gomella, MD

3:40 PM – 4:00 PM            Panel Discussion - Moderator: Daniel P. Petrylak, MD, Panelists Kamat, Gomella, Lerner, Pinthus

 4:00 PM                                  Closing Remarks

Westin Riverfront at Beaver Creek
126 Riverfront Lane
Avon, CO 81620
United States
+1 (888) 627-8099
Westin Hotel and Resort

PROGRAM CHAIR

E. David Crawford, MD, University of Colorado, Denver School of Medicine, Aurora, CO

 

IBCU Co-Chairs:

Michael S. Cookson, MD, MMHC, University of Oklahoma College of Medicine, Norman, OK                                   

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT

 

IBCU FACULTY:

Peter Black, MD, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

Sam S. Chang, MD, Vanderbilt University School of Medicine, Nashville, TN

Leonard G. Gomella, MD, Thomas Jefferson University, Philadelphia, PA

Ashish M. Kamat, MD, MBBS, FACS, The University of Texas, MD Anderson Cancer Center, Houston, TX

Seth P. Lerner, MD, Baylor College of Medicine, Houston, TX

Jehonathan Pinthus, MD, PhD, McMaster University, Hamilton, ON, Canada

Neal D. Shore, MD, Carolina Urologic Research Center, Atlantic Urology Clinics, LLC, Myrtle Beach, SC

Dan Theodorescu, MD, PhD, University of Colorado Comprehensive Cancer Center, Aurora, CO

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.


CREDIT DESIGNATION
MCW designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available Credit

  • 5.75 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 5.75 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.